Phaseline

Companies › ScinnoHub Pharmaceutical

ScinnoHub Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Hematology, Genitourinary, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BT-114143 Injection–Phase 2Total Knee Arthroplasty; Abnormal Uterine BleedingDec 2026
SNH-119014
Pyruvate kinase red blood cell isozyme (PKR) agonist
PKLRPhase 1Hemoglobinopathy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07169214BT-114143 InjectionPhase 1Abnormal Uterine BleedingGenitourinarySep 2025
NCT07087262SNH-119014Phase 1HemoglobinopathyHematologyMar 2026
NCT07127042BT-114143 InjectionPhase 2Total Knee ArthroplastyOtherDec 2026

Targets

PKLR (1)

Companies with the same targets

Forma Therapeutics Agios Pharmaceuticals Novo Nordisk

Companies built like this

Forma Therapeutics Agios Pharmaceuticals Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Shanghai Bao Pharmaceuticals Akebia Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.